Ondansetron (Zofran ODT) in Pregnancy: Safety Profile and Guidelines
Current Evidence-Based Guidance
Ondansetron (5-HT3 antagonist) is widely used for nausea/vomiting in pregnancy (NVP), including hyperemesis gravidarum.
First Trimester (Weeks 0–13)
- Large cohort studies (Nordic, Medicaid) show no significant increase in major congenital malformations overall.
- Slight absolute risk increase for cleft palate (~0.3% vs 0.1% baseline) in some studies; not consistently replicated.
- ACOG: Consider after failed first-line (doxylamine/B6); not first-line.
Second/Third Trimester
- Less data; theoretical concern for fetal serotonin receptor effects.
- No clear evidence of cardiac defects, growth restriction, or preterm birth.
- Use if benefits outweigh risks; lowest effective dose.
Practical Recommendations
- First-line: Lifestyle/dietary changes → Vitamin B6 (25 mg TID) ± Doxylamine (12.5 mg TID) [Diclegis/Bonjesta].
- Second-line: Ondansetron 4–8 mg PO/IV/ODT q8h PRN.
- Monitor for: QT prolongation (ECG if risk factors), constipation, headache, serotonin syndrome (with other serotonergic drugs).
- Reassess need each trimester.
Key Points
- ODT formulation useful if swallowing difficult.
- Not FDA-approved for NVP (off-label); extensive real-world use.
- Discuss with OB provider; individualize based on severity, comorbidities, gestational age.
Babies & Teething - Related Articles
- Irregular Periods in 13‑Year‑Olds: Causes & When to See a Doctor
- Gripe Water for Teething & Colic: Parent's Guide
- First Dental Visit for Children: AAPD Guidelines & What to Expect
- Jack Russell Puppy Teething: Canine Tooth Eruption & Removal - What You Need to Know
- Baby Powder Ingestion: Risks, Symptoms, and Emergency Steps
- Baby's First Smile: Timeline, Types, and Developmental Significance
- Wisdom Tooth Extraction for Teens: A Comprehensive Guide
